NICEVIVA
DRUG INTERACTION RECORDED 1 Prescription Drug Interaction(s) Reported — Review the pharmacokinetic interaction matrix below before use.
Pharmacokinetic Alert
MONOGRAPH SPEC LATEST 2026

Calcium (Hydroxyapatite)

MINERALS · Evidence Monograph

Calcium (Hydroxyapatite) is an evidence-graded minerals monograph evaluated across 41 peer-reviewed PubMed studies (3 meta-analyses, 5 systematic reviews, and 2 randomized controlled trials, encompassing n = 13,798 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for electrolyte balance, neuromuscular signaling, and enzymatic cofactor activity.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 41 Studies
Meta-Analyses · Reviews 3 Meta · 5 Systematic Reviews
Randomized Trials (RCT) 2 RCTs (3 Double-Blind)
Cumulative Participants n = 13,798
Trial Duration Range 90 days · 60 weeks · 4 weeks
Reading Time ~21 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for electrolyte balance, neuromuscular signaling, and enzymatic cofactor activity (supported by 41 indexed PubMed studies, GRADE High).
  2. 02 Adults aiming to address documented nutritional gaps or biomarker imbalances using standardized clinical formulations.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Amino-Acid Chelate (Bisglycinate) or Organic Citrate Salt
Avoid low-bioavailability inorganic oxides or carbonates if you have a sensitive stomach; organic chelates minimize GI irritation and transporter competition.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Smooth gastrointestinal tolerance without bloating, cramps, or osmotic loose stools.
Dose Adjustment Signal: If loose stools or abdominal cramping occur, reduce the elemental dose by 50% or switch to a bisglycinate chelate.
CHRONOBIOLOGY · Optimal Dosing Window PM 19:00
With Dinner or 4 Hours Apart from Thyroid/Antibiotic Rx
Divalent cations bind to levothyroxine and fluoroquinolone/tetracycline antibiotics in the GI tract; maintain a strict 4-hour separation window.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary minerals clinical efficacy (41 PubMed studies)
Quantitative biomarker & outcome analysis (11 studies with effect-size/sample data)
Randomized controlled trial verification (2 RCTs · 3 double-blind)
Systematic review & meta-analysis synthesis (3 meta-analyses · 5 reviews)
01

What Is Calcium (Hydroxyapatite) & Why Does Form Matter?

Calcium (Hydroxyapatite) is classified under MINERALS and has been investigated across 41 peer-reviewed PubMed publications for its role in electrolyte balance, neuromuscular signaling, and enzymatic cofactor activity.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (see individual study protocols).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Calcium (Hydroxyapatite) frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (2 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Calcium (Hydroxyapatite) acts on pathways governing electrolyte balance, neuromuscular signaling, and enzymatic cofactor activity. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Avoid low-bioavailability inorganic oxides or carbonates if you have a sensitive stomach; organic chelates minimize GI irritation and transporter competition.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Calcium (Hydroxyapatite) an overall evidence rating of GRADE High (4.0 / 4.0) based on 41 PubMed studies: 3 meta-analyses, 5 systematic reviews, and 2 randomized controlled trials (3 double-blind, n = 13,798 total participants).

Representative peer-reviewed findings include: • PMID:41669823 (2026) — "Calcium Hydroxyapatite and Polymicronutrient Solution on Hand Rejuvenation: A Split-Hand, Randomized, Double-Blind Clinical and In Vitro Study." (CONCLUSION: Both treatments demonstrated comparable clinical outcomes, suggesting that the strong biostimulating effect of CaHA may have overshadowed potential additive effects of PMN.) • PMID:39099032 (2024) — "Supraperiosteal technique protocol for forehead filling with a mixture of calcium hydroxyapatite and hyaluronic acid: Double-blind, randomized controlled clinical trial." (CONCLUSION: The supraperiosteal application of CaHA and HA for forehead treatment demonstrates superior efficacy in addressing signs of aging compared to the isolated use of CaHA.) • PMID:38934231 (2024) — "Long-term duration and safety of Radiesse (+) for the treatment of jawline." (CONCLUSIONS: CaHA-CMC(+) produced clinically meaningful and long-lasting improvements in jawline contour and was well tolerated in patients through 60 weeks.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Amino-Acid Chelate (Bisglycinate) or Organic Citrate Salt. Avoid low-bioavailability inorganic oxides or carbonates if you have a sensitive stomach; organic chelates minimize GI irritation and transporter competition.

Clinical Trial Dosing & Timing: Optimal timing window: PM 19:00 · With Dinner or 4 Hours Apart from Thyroid/Antibiotic Rx (Divalent cations bind to levothyroxine and fluoroquinolone/tetracycline antibiotics in the GI tract; maintain a strict 4-hour separation window.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Smooth gastrointestinal tolerance without bloating, cramps, or osmotic loose stools.

Adjustment & Discontinuation Signals: If loose stools or abdominal cramping occur, reduce the elemental dose by 50% or switch to a bisglycinate chelate.

07

Prescription Drug Interactions & Contraindications

• [MODERATE] Levothyroxine: Pharmacokinetic or pharmacodynamic interaction reported in clinical literature (PMID:15355898). Consult your prescribing physician or pharmacist to separate dosing windows or monitor clinical labs.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 19:00 · With Dinner or 4 Hours Apart from Thyroid/Antibiotic Rx) with a full glass of water.
  • Start at a conservative single-serving dose for the first 5–7 days to verify gastrointestinal tolerance.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist before use if taking Levothyroxine.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (41 Studies) · 11 Quantitative Analyses

01
RANDOMIZED TRIAL (RCT) Journal of cosmetic dermatology (2026) PMID: 41669823 ↗
Calcium Hydroxyapatite and Polymicronutrient Solution on Hand Rejuvenation: A Split-Hand, Randomized, Double-Blind Clinical and In Vitro Study.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in Journal of cosmetic dermatology involving n = 22 participants; statistical significance reported at p = 0.001. Key conclusion: CONCLUSION: Both treatments demonstrated comparable clinical outcomes, suggesting that the strong biostimulating effect of CaHA may have overshadowed potential additive effects of PMN.
View Original PubMed Abstract ↓

BACKGROUND: Calcium hydroxyapatite (CaHA) is a well-established biostimulatory filler approved for hand rejuvenation. Recent approaches have explored dilution with polymicronutrient (PMN) solutions to enhance cellular metabolism and extracellular matrix (ECM) regeneration. AIMS: To evaluate the biological and clinical effects of CaHA diluted in a PMN solution (CaHA + PMN) compared with the conventional CaHA diluted in saline solution (CaHA + SS) for hand rejuvenation. METHODS: An in vitro study was conducted to assess fibroblast proliferation and gene expression of ECM components (COL1A1, COL3A1, and ELN) after exposure to CaHA diluted with PMN or SS. A prospective, split-hand, double-blind clinical trial (n = 22) compared both formulations regarding Hand Grading Scale (HGS), Global Aesthetic Improvement Scale (GAIS), skin hydration (corneometry), and dermal thickness (ultrasound imaging) at baseline, 15 and 90 days after treatment. RESULTS: In vitro, CaHA + PMN induced greater fibroblast proliferation and upregulated COL1A1 and ELN gene expression compared to CaHA + SS. Clinically, both treatments led to significant improvement from baseline in HGS (p < 0.001), skin hydration and dermal/hypodermal thickness, with no statistically significant differences between-group. Investigator-assessed GAIS and patient-reported satisfaction on a 5-point Likert scale also showed improvement in both groups. CONCLUSION: Both treatments demonstrated comparable clinical outcomes, suggesting that the strong biostimulating effect of CaHA may have overshadowed potential additive effects of PMN. Nonetheless, in vitro findings confirmed enhanced biological activity with CaHA + PMN, supporting its investigation as a complementary strategy in future studies. © 2026 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

02
RANDOMIZED TRIAL (RCT) Journal of cosmetic dermatology (2024) PMID: 39099032 ↗
Supraperiosteal technique protocol for forehead filling with a mixture of calcium hydroxyapatite and hyaluronic acid: Double-blind, randomized controlled clinical trial.
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Journal of cosmetic dermatology involving n = 132 participants. Key conclusion: CONCLUSION: The supraperiosteal application of CaHA and HA for forehead treatment demonstrates superior efficacy in addressing signs of aging compared to the isolated use of CaHA.
View Original PubMed Abstract ↓

OBJECTIVE: The current study aims to investigate the safety and efficacy of using calcium hydroxyapatite (CaHA) versus CaHA associated with hyaluronic acid (HA) for forehead volume replacement and contour restoration without forehead irregularities. METHODS: This interventional study involved 132 participants in a two-arm, parallel, double-blind trial for forehead treatment using the supraperiosteal technique. Group A received CaHA, and Group B received a combination of CaHA and HA as filler materials. Follow-up assessments occurred at 30 and 180 days, incorporating the 5-point Global Aesthetic Improvement Scale (GAIS) and photographic analysis for forehead volume replacement, contour restoration, and without forehead irregularities. Safety assessments included monitoring adverse events, particularly nodules. RESULTS: The study included all 132 enrolled patients who completed the trial. Applying CaHA in combination with HA resulted in a statistically significant improvement in both GAIS scale scores and the reduction of forehead irregularities. The total incidence of nodules was 3.7%. Group A had four times more occurrences of nodules than Group B. Furthermore, Group B exhibited lower rates of forehead irregularities following the treatment compared to Group A. CONCLUSION: The supraperiosteal application of CaHA and HA for forehead treatment demonstrates superior efficacy in addressing signs of aging compared to the isolated use of CaHA. © 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

03
CLINICAL STUDY Journal of cosmetic dermatology (2024) PMID: 38934231 ↗
Long-term duration and safety of Radiesse (+) for the treatment of jawline.
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Journal of cosmetic dermatology. Key conclusion: CONCLUSIONS: CaHA-CMC(+) produced clinically meaningful and long-lasting improvements in jawline contour and was well tolerated in patients through 60 weeks.
View Original PubMed Abstract ↓

BACKGROUND: Calcium hydroxyapatite (CaHA)-carboxymethylcellulose (CMC)+ has unique properties that make it optimal for lifting, contouring, and defining the jawline. This long-term follow-up of a randomized, multicenter, rater-blinded trial reports efficacy and safety of CaHA-CMC(+) through 48 and up to 60 weeks post-treatment. METHODS: Eligible patients were randomized (2:1) to the treatment or the control/delayed treatment group to receive CaHA-CMC(+) injections in both jawlines. While touch-ups were permitted 4 weeks post-treatment for both groups, only the treatment group was eligible for optional retreatment after 48 weeks. The primary outcome was ≥1-point improvement on both jawlines on the Merz Jawline Assessment Scale (MJAS); secondary endpoints included the Subject Global Aesthetic Improvement Scale (SGAIS) among others. Post hoc analysis included pooling up to 48-week data from the combined treatment and control/delayed groups and 60-week data for the treatment group. RESULTS: Overall, 175 received treatment. MJAS responder rates were 77.9%, 78.7%, and 62.9% at 12, 24, and 48 weeks post-treatment, respectively. Responder rate on the MJAS at 60 weeks was 74.6% for those who received retreatment and 43.5% for those patients who received only the initial and touchup treatments. SGAIS scores demonstrated 93.4%, 85.6%, and 68.5% of patients rated themselves very much improved after 12, 24, and 48 weeks, respectively. Adverse events consisted of procedure or CaHA-CMC(+)-related events that were mostly resolved and overwhelmingly mild. CONCLUSIONS: CaHA-CMC(+) produced clinically meaningful and long-lasting improvements in jawline contour and was well tolerated in patients through 60 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03583359. © 2024 The Author(s). Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.

04
CLINICAL STUDY Aesthetic plastic surgery (2024) PMID: 38831064 ↗
Hand Rejuvenation with Customizable Hybrid Fillers: Premixed Calcium Hydroxyapatite and Hyaluronic Acid.
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Aesthetic plastic surgery. Key conclusion: CONCLUSION: Premixed filler containing HA and CaHA for hand rejuvenation appears to be a safe and effective approach.
View Original PubMed Abstract ↓

INTRODUCTION: Hand aging is a prevalent concern characterized by the atrophy of local soft tissues and increased visibility of vessels and tendons. Hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) are well-established treatments for addressing this issue. While hybrid filler containing HA and CaHA has been proposed for facial rejuvenation, studies investigating its efficacy for hand rejuvenation are lacking. OBJECTIVE: This study aims to assess the safety and efficacy of a premixed hybrid filler containing calcium hydroxyapatite (CaHA) and hyaluronic acid (HA) for hand rejuvenation. METHODS: A prospective, double-blind, controlled trial was conducted. The control arm (CA) received conventional subdermal treatment with CaHA at a 1:1 dilution. The intervention arm (IA) underwent hybrid treatment, consisting of CaHA at a 1:1 dilution combined with 1 ml of low-density HA. Evaluation was performed subjectively using the Global Aesthetic Improvement Scale (GAIS) and the Manchester Hand Grading System (MHGS), and objectively using cutometry, corneometry, and ultrasound. RESULTS: Both the CA and the IA exhibited high rates of patient satisfaction and satisfaction as assessed by blinded evaluators. Although numerical superiority was observed in the IA, no statistical difference was found between the two groups. Significant improvements in hydration, elasticity, and skin thickness were observed in both arms, with no discernible difference between them. Greater ultrasound echogenicity was noted in the IA, which, as indicated by existing literature, may suggest enhanced biostimulation. No adverse effects were reported in either arm. CONCLUSION: Premixed filler containing HA and CaHA for hand rejuvenation appears to be a safe and effective approach. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 . © 2024. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.

05
CLINICAL STUDY Aesthetic plastic surgery (2024) PMID: 37673803 ↗
Treatment of Atrophy of the Labia Majora: Calcium Hydroxyapatite or Hyaluronic Acid?
Clinical Trial Synthesis 2024 Randomized Controlled Trial (RCT) published in Aesthetic plastic surgery; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: CaHA and HA are both effective and safe for treating the intimate region, and this study cannot prove the superiority of one over the other.
View Original PubMed Abstract ↓

PURPOSE: The study aimed to evaluate and compare the efficacy and safety of treating atrophied labia majora with hyaluronic acid (HA) and calcium hydroxyapatite (CaHA). METHODS: Ten participants complaining of sagging or loss of volume in the labia majora were evaluated and randomly assigned to two groups-treated with CaHA or AH. Photographic documentation was taken and appreciated by the participants and by blind observers. RESULTS: The study showed an improvement in labia majora regarding volumization and flaccidity that was more significant after 90 days of treatment in both treatments. Besides flaccidity, volume replacement resulted in better balance and proportion between the labia majora and labia minora. The evaluators, independent and blind, judged that in 80% of the cases of the HA group and in 50% of cases of the CaHA group, there was an excellent improvement. CONCLUSION: CaHA and HA are both effective and safe for treating the intimate region, and this study cannot prove the superiority of one over the other. An appropriate assessment involving the analysis of sagging and/or volume loss and the creation of a sequential treatment protocol, involving CaHA and HA, seems to be the best solution. LEVEL OF EVIDENCE I: Evidence obtained from at least one properly designed randomized controlled trial. This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 . © 2023. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.

06
CLINICAL STUDY The Journal of clinical dentistry (2011) PMID: 21702326 ↗
Comparison of fluoride uptake into tooth enamel from two fluoride varnishes containing different calcium phosphate sources.
Clinical Trial Synthesis 2011 Clinical Study published in The Journal of clinical dentistry; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: The ACP varnish formulation delivers statistically significantly more fluoride to both intact and demineralized enamel than the formulation containing TCP.
View Original PubMed Abstract ↓

OBJECTIVE: The objective of this in vitro study was to compare two 5% sodium fluoride varnishes, each containing different sources of calcium and phosphate, for their ability to deliver fluoride into treated sound tooth enamel and adjacent, but untreated demineralized enamel. METHODS: Six sets of 12 bovine enamel cores were mounted in plexiglass rods and the exposed surfaces were polished. Synthetic lesions were formed in the surface of three sets by soaking in thickened, pH 5.0, 1M lactic acid, 50% saturated with calcium hydroxyapatite. A fluoride varnish containing tri-calcium phosphate (TCP) was applied to one set of sound enamel cores, and a second, delivering amorphous calcium phosphate (ACP), was applied to another. A third set of sound enamel cores was water-treated. Each treated sound core was paired with an untreated lesioned core, and the pairs were soaked in artificial saliva for 24 hours at 37 degrees C. The treated cores, but not their lesioned counterparts, were initially soaked in 1.0 N KOH saturated with calcium phosphate for 18 hours. Each core was separately etched with 1.0 N perchloric acid for exactly 15 seconds, and fluoride measured by an ion-sensitive electrode after neutralizing with NaOH and buffering in TISAB II. The amount of calcium extracted was also determined by atomic absorption spectrophotometry as a measure of etch depth. RESULTS: Fluoride uptake average was 1677 +/- 193 ppm, 455 + 38 ppm, and 44 +/- 5 ppm for the sound enamel cores treated with ACP varnish, TCP varnish, and water treatment, respectively. Fluoride uptake into the demineralized enamel averaged 5567 +/- 460 ppm, 2126 +/-126 ppm, and 49 -/+ 4 ppm for demineralized enamel paired with the sound cores treated with ACP varnish, TCP varnish, and water, respectively. The differences between the ACP varnish, the TCP varnish, and the water treatments were statistically significant (p < 0.05). CONCLUSION: The ACP varnish formulation delivers statistically significantly more fluoride to both intact and demineralized enamel than the formulation containing TCP.

07
SYSTEMATIC REVIEW Aesthetic plastic surgery (2026) PMID: 41184662 ↗
Efficacy, Durability, and Safety of Collagen Biostimulators Based on Poly-L-Lactic Acid (PLLA) and Calcium Hydroxyapatite (CaHA) in the Face: A Systematic Review.
Clinical Trial Synthesis 2026 Systematic Review published in Aesthetic plastic surgery. Key conclusion: CONCLUSION: Both PLLA and CaHA are effective and safe biostimulators for facial rejuvenation.
View Original PubMed Abstract ↓

BACKGROUND: Collagen biostimulators, such as poly-L-lactic acid (PLLA) and calcium hydroxyapatite (CaHA), are widely used in facial esthetic treatments to improve skin quality, restore volume, and stimulate neocollagenesis. OBJECTIVE: This study aimed to evaluate the efficacy, durability, and safety of PLLA- and CaHA-based collagen biostimulators in facial esthetic treatments. METHODS: A systematic literature review was conducted following PRISMA 2020 guidelines. The PICO strategy guided the research question. Searches were performed in April 2024 in the BVS, Medline (via PubMed), and Scopus databases, using standardized descriptors and Boolean operators. Studies published between 2010 and 2024, available in full text in Portuguese, English, or Spanish, were included. Screening was conducted using the Rayyan platform, and the quality of included studies was assessed with the ROB2 tool. RESULTS: Fourteen studies met the eligibility criteria. Both PLLA and CaHA demonstrated significant improvements in skin elasticity, wrinkle reduction, and increased facial volume. PLLA maintained its effects for up to 25 months, while CaHA offered results lasting 12 to 18 months. The most frequent adverse effects were mild, including pain and swelling at the injection site. One serious case of compression necrosis was reported with CaHA. CONCLUSION: Both PLLA and CaHA are effective and safe biostimulators for facial rejuvenation. However, further research is needed to standardize techniques and assess long-term safety. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 . © 2025. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.

08
META-ANALYSIS Aesthetic surgery journal (2025) PMID: 40674466 ↗
Biostimulants in Aesthetic Medicine: A Systematic Review and Meta-analysis of Efficacy, Safety, and Patient Satisfaction.
Clinical Trial Synthesis 2025 Meta-Analysis published in Aesthetic surgery journal. Key conclusion: Among studies not included in the meta-analysis, all parameters studied showed significant improvements in terms of dermal, volume, anatomic, and satisfaction outcomes.
View Original PubMed Abstract ↓

63. Aesthet Surg J. 2025 Nov 17;45(12):1278-1284. doi: 10.1093/asj/sjaf142. Biostimulants in Aesthetic Medicine: A Systematic Review and Meta-analysis of Efficacy, Safety, and Patient Satisfaction. Smith L, Rahmati M, Pizzol D, López-Sánchez GF, Boyer L, Fond G, Tran BX, Gawronska J, Yon DK, Ravindran R. Biostimulants, including calcium hydroxyapatite, poly-L-lactic acid, and polycaprolactone, have become popular in aesthetic medicine as they lead to long-term tissue rejuvenation. However, their efficacy (eg, dermal, volume, and anatomic outcomes), patient satisfaction, and safety remain unclear. This systematic review and meta-analysis collates and appraises the available data on biostimulants, examining their efficacy, adverse events, and patient satisfaction. A comprehensive search was conducted in PubMed/Medline (National Library of Medicine, Bethesda, MD), Scopus (Elsevier, Amsterdam, the Netherlands), Embase (Elsevier), and Web of Science (Clarivate, Philadelpha, PA), up to January 14, 2025. Studies were included that assessed the effects of biostimulants on efficacy, adverse events, and patient satisfaction in observational studies. Meta-analyses using random-effects models were performed on individual proportions and applied to 7 outcomes (satisfaction, bruising, ecchymosis, edema, erythema, nodule development, pain). A total of 197 articles were screened, and 25 studies were included in the systematic review. The results of meta-analyses indicate that the pooled satisfaction rate of biostimulants was estimated to be 91% (95% CI, 67%-98%; I2 = 87.3%), with the following adverse event rates: bruising, 27% (95% CI, 12%-50%; I2 = 96%); ecchymosis, 22% (95% CI, 11%-40%; I2 = 95.5%); edema, 5% (95% CI, 1%-18%; I2 = 93.6%); erythema, 16% (95% CI, 4%-47%; I2 = 94.3%); nodule development, 5% (95% CI, 2%-10%; I2 = 85.5%); pain, 92% (95% CI, 63%-99%; I2 = 87.7%). Among studies not included in the meta-analysis, all parameters studied showed significant improvements in terms of dermal, volume, anatomic, and satisfaction outcomes. Biostimulants demonstrate clinical promise and a favorable tolerability profile in aesthetic medicine despite the common occurrence of

09
META-ANALYSIS Journal of plastic, reconstructive & aesthetic surgery (2025) PMID: 40499276 ↗
Complications of alloplastic facial skeletal implants in aesthetic surgery: A systematic review and meta-analysis.
Clinical Trial Synthesis 2025 Meta-Analysis published in Journal of plastic, reconstructive & aesthetic surgery involving n = 3,701 participants. Key conclusion: CONCLUSION: Alloplastic facial implants are a viable alternative to enhancing facial beauty and performing facial skeletal augmentation with a relatively lower risk of complications associated with all facial implants.
View Original PubMed Abstract ↓

OBJECTIVE: This study aimed to evaluate the effectiveness of various alloplastic facial implants in correcting facial defects based on post-operative complications and failure rates in patients who underwent facial skeletal augmentation. METHOD: A comprehensive search for articles reporting relevant articles was using Google Scholar and PubMed databases. Data from publications that satisfied the predefined inclusion criteria were synthesized and analyzed using OpenMeta [Analyst] software. RESULTS: A total of 48 studies with a population size of 3701 patients who received 4139 alloplastic facial implants were included in this analysis. The complication rate was 10.7% (95% confidence intervals [CI] [8.3%, 13.2%], and I2 =89.35%). Paranasal implants had the highest rate of complications of 15.1% (95% CI [7.8%, 22.3%], and malar implants had the lowest complication rate of 7.4% (95% CI 3.8%, 11.1%]) I2 = 72.62%). In 15 studies that had malar implants, 853/1788 (45.8%) of the patients received malar implants (95% CI [0.356, 0.561]). In 8 studies that included mandibular implants, 265 (56%) of 508 patients received mandibular implants (95% CI [0.474, 0.645]); in 11 studies, 371/489 (76.1%) received nasal or paranasal implants (95% CI of [0.565, 0.912]), while in 3 studies, 14/15 (85.5%) received frontal implant (95% CI of [0.645, 0.997]). In 17 studies that investigated the use of chin implants, 1366/1366 (100%) of the eligible patients received chin implants (95% CI [0.995, 1.000], I2 = 0%). The complication rate was 2.78% for silicone, 1.02% for calcium hydroxyapatite, and 2.48 for Medpor. CONCLUSION: Alloplastic facial implants are a viable alternative to enhancing facial beauty and performing facial skeletal augmentation with a relatively lower risk of complications associated with all facial implants. Crown Copyright © 2025. Published by Elsevier Ltd. All rights reserved.

10
SYSTEMATIC REVIEW Aesthetic plastic surgery (2024) PMID: 38862661 ↗
Nonsurgical Rhinoplasty: An Updated Systematic Review of Technique, Outcomes, Complications, and Its Treatments.
Clinical Trial Synthesis 2024 Systematic Review published in Aesthetic plastic surgery involving n = 9,657 participants. Key conclusion: CONCLUSIONS: Nonsurgical rhinoplasty is an effective and relatively safe option for improving the profile of the nose, with a short operative time and high patient satisfaction.
View Original PubMed Abstract ↓

BACKGROUND: For patients looking for temporary results or who do not want surgery, nonsurgical rhinoplasty using filler injections has become increasingly popular. Filler materials and surgical techniques have improved in recent years, but serious complications remain. Therefore, the aim of this systematic review is to summarize the common types of fillers and injection techniques, complications, and treatment to help clinicians perform in a safer and more effective way. METHODS: A systematic review was performed using keywords and Medical Subject Headings search terms. PubMed, Embase, and the Cochrane Library were searched using the appropriate search terms. Data collected from each study included injection materials, location, technique, patient satisfaction and complications, and treatment. RESULTS: From the 1812 studies identified, 30 were included in the systematic review. A total of 9657 patients underwent nonsurgical rhinoplasty, most commonly with hyaluronic acid (HA) (96.76%), followed by calcium hydroxyapatite (CaHA) (1.22%). Overall satisfaction was 99.08%. The overall incidence of complications was 39.11%, with the highest incidence of erythema and swelling (27.95%). Most of the complications are mild, but there are still 0.27% of the patients who have undergone severe complication-an arterial occlusion. CONCLUSIONS: Nonsurgical rhinoplasty is an effective and relatively safe option for improving the profile of the nose, with a short operative time and high patient satisfaction. Most of the complications were mild, but still serious vascular complications such as blindness, skin necrosis, and stroke were as high as 0.27%. A thorough understanding of the anatomy of the nasal vessels and a precise surgical technique is an important basis for prevention. A BULLET POINT LIST: (1) We summarize the common types of fillers and injection techniques, complications, and treatment of complications to guide physicians to perform nonsurgical rhinoplasty in a safer and more effective manner. (2) Out of 1812 studies through the search strategy, 30 articles were included in the systematic review. A total of 9657 patients underwent nonsurgical rhinoplasty. (3) Nonsur

RELATED MONOGRAPHS

Related Monographs in This Category